This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): filgrastim, G-CSF
Description: Neupogen, like natural G-CSF, stimulates the production of the infection fighting white blood cells called neutrophils.
Revenue splits for this drug are BioMedTracker estimates.
Roche and Amgen
Neupogen is marketed by Amgen in the U.S. and is co-marketed with Roche in Europe. In May 2002, Amgen paid Roche $137.5 million for certain rights related to the commercialization of Neupogen and Neulasta in the European Union, Switzerland, and Norway.
In October 2013, Amgen announced that it has entered into a definitive agreement with Roche to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014. Amgen will begin distributing and selling product as soon as practical in countries where the Company has an existing commercial presence. In countries where Amgen does not have a presence, Roche or its distributors will continue to sell and distribute the products for an interim transition period. Kyowa Hakko Kirin Co., Ltd. of Japan will continue to retain product rights and market filgrastim and pegfilgrastim in some selected Asian...See full deal structure in Biomedtracker
Partners: Roche Holding AG Kyowa Hakko Kirin Co., Ltd. DRI Capital Inc.
Additional information available to subscribers only: